Venture Capital Iv, L.P.Ver... Net Worth

The estimated Net Worth of Venture Capital Iv, L.P.Ver... is at least $543 Thousand dollars as of 16 November 2011. Venture Ver owns over 665,488 units of IVERIC bio Inc stock worth over $543,320 and over the last 13 years Venture sold ISEE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Ver ISEE stock SEC Form 4 insiders trading

Venture has made over 1 trades of the IVERIC bio Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Venture bought 665,488 units of ISEE stock worth $26,586,246 on 16 November 2011.

The largest trade Venture's ever made was buying 665,488 units of IVERIC bio Inc stock on 16 November 2011 worth over $26,586,246. On average, Venture trades about 166,372 units every 0 days since 2011. As of 16 November 2011 Venture still owns at least 13,600 units of IVERIC bio Inc stock.

You can see the complete history of Venture Ver stock trades at the bottom of the page.

What's Venture Ver's mailing address?

Venture's mailing address filed with the SEC is One Sansome Street, 1 Sansome St, San Francisco, CA 94104, USA.

Insiders trading at IVERIC bio Inc

Over the last 6 years, insiders at IVERIC bio Inc have traded over $8,677,595 worth of IVERIC bio Inc stock and bought 130,569 units worth $624,325 . The most active insiders traders include Glenn Sblendorio, Venture Capital Iv, L.P.Ver..., and Keith Westby. On average, IVERIC bio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $848,338. The most recent stock trade was executed by Keith Westby on 3 July 2023, trading 20,000 units of ISEE stock currently worth $58,800.

What does IVERIC bio Inc do?

we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).

Complete history of Venture Ver stock trades at Clovis Oncology Inc and IVERIC bio Inc

IVERIC bio Inc executives and stock owners

IVERIC bio Inc executives and other stock owners filed with the SEC include:

• Glenn Sblendorio,
  President, Chief Executive Officer, Director
• David Guyer,
  Executive Chairman of the Board
• Anthony S. Gibney,
  Exec. VP and Chief Bus. & Strategy Officer
• David Carroll,
  Chief Financial Officer, Senior Vice President, Treasurer
• Keith Westby,
  Chief Operating Officer, Senior Vice President
• Glenn P. Sblendorio M.B.A.,
  CEO & Director
• Dr. Pravin U. Dugel M.D.,
  Pres
• David F. Carroll M.B.A.,
  Sr. VP, CFO & Treasurer
• Christopher Paul Simms,
  Sr. VP & Chief Commercial Officer
• David F. Carroll,
  Sr. VP, CFO & Treasurer
• Keith Westby M.B.A.,
  Sr. VP & COO
• Calvin Roberts,
  Independent Director
• Jane Henderson,
  Independent Director
• Adrienne Graves,
  Lead Independent Director
• Axel Bolte,
  Independent Director
• Kathy Galante,
  Vice President, Investor Relations and Corporate Communications
• Mark Blumenkranz,
  Director
• Abraham Scaria,
  Chief Scientific Officer
• Evelyn Harrison,
  Sr. VP & Chief Clinical Operations Officer
• Amy R. Sheehan,
  Sr. VP & Chief HR Officer
• Todd D.C. Anderman,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Dr. Xiao-Ping Dai Ph.D.,
  Chief Technical Officer
• Dr. Samir C. Patel,
  Co-Founder and Consultant
• Christopher Paul Simms,
  SVP, Chief Commercial Officer
• Christine Ann Miller,
  Director
• David E Redlick,
  Director
• Venture Capital Iv, L.P.Ver...,
  
• Anthony S Gibney,
  EVP, Chief Business Officer
• Pravin Dugel,
  President